Isabella Watts
Overview
Explore the profile of Isabella Watts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Appanna N, Mew R, Williams S, Starkey T, Patel G, Hudson L, et al.
Int J Cancer
. 2025 Mar;
PMID: 40062998
SARS-CoV-2 continues to spread across the world as a highly transmissible endemic disease. For many cancer patients, SARS-CoV-2 infection is unavoidable. It continues to disrupt cancer care, causing treatment delays...
2.
Watts I, Houston H, Gorton R, Stone N
Clin Infect Dis
. 2024 May;
80(2):485-487.
PMID: 38735656
No abstract available.
3.
Starkey T, Ionescu M, Tilby M, Little M, Burke E, Fittall M, et al.
Sci Rep
. 2023 Jul;
13(1):11327.
PMID: 37491478
Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since...
4.
Chhaya S, Watts I, Ng K, Mustapha R, Powles T, Sharma A, et al.
Oncol Ther
. 2023 Jan;
11(1):49-64.
PMID: 36595203
Objective: We aim to describe and highlight the current use of immune checkpoint inhibitors (ICIs) in the muscle invasive bladder cancer (MIBC) treatment landscape, particularly focusing on the perioperative setting....
5.
Lee L, Tilby M, Starkey T, Ionescu M, Burnett A, Hattersley R, et al.
JAMA Oncol
. 2022 Dec;
9(2):188-196.
PMID: 36547970
Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is...
6.
Appanna N, Patel G, Burke E, Burnett A, Clark J, Mew R, et al.
Int J Cancer
. 2022 Dec;
152(6):1275-1277.
PMID: 36454180
No abstract available.
7.
Lee L, Ionescu M, Starkey T, Little M, Tilby M, Tripathy A, et al.
Eur J Cancer
. 2022 Sep;
175:1-10.
PMID: 36084618
Purpose: People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters...
8.
Lee L, Starkey T, Ionescu M, Little M, Tilby M, Tripathy A, et al.
Lancet Oncol
. 2022 May;
23(6):748-757.
PMID: 35617989
Background: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against...
9.
Watts I, Smith D, Mounter S, Baker E, Hitchings A, Gill D
Br J Clin Pharmacol
. 2021 Oct;
88(4):1935-1941.
PMID: 34694650
The ChAdOx1 nCoV-19 vaccine has been associated with increased risk of thrombosis. Understanding of the management of these rare events is evolving, and currently recommended treatments include human normal immunoglobulin...
10.
Brown E, Watts I, Beales E, Maudhoo A, Hayward J, Sheridan E, et al.
Genet Med
. 2021 Apr;
23(8):1438-1449.
PMID: 33824502
Purpose: The COVID-19 pandemic has forced reorganization of clinical services to minimize face-to-face contact between patients and health-care providers. Specialist services, including clinical genetics, must consider methods of remote delivery...